What question did this study set out to answer?

This review explores how the biologic context affects the efficacy of immunotherapy in head and neck squamous cell carcinoma (HNSCC).

August 2, 2026OncoOpen Access

Rethinking Immunotherapy Drug Development in Head and Neck Squamous Cell Carcinoma: The Role of Biologic Context and Treatment Sequencing

View Full Paper

Ask AI

Bookmark

Authors

This review analyzes treatment sequencing's impact on immunotherapy efficacy in head and neck cancer, suggesting biologically informed strategies.

This review explores how the biologic context affects the efficacy of immunotherapy in head and neck squamous cell carcinoma (HNSCC).
Integration of clinical trial evidence from recurrent/metastatic and locally advanced disease settings.
Examining the influence of tumor antigen availability, host immune competence, and timing of immunotherapy.
Analyzing meta-analyses and randomized trials related to neoadjuvant and adjuvant checkpoint inhibition.
Checkpoint blockade is effective when tumor antigen availability and immune function are intact.
Limited survival improvements were noted in unselected populations with concurrent or adjuvant therapies.
The effectiveness of immunotherapy varies significantly across different biological contexts.

Sajid et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

This review analyzes treatment sequencing's impact on immunotherapy efficacy in head and neck cancer, suggesting biologically informed strategies.